NEW YORK (GenomeWeb) – CombiMatrix this week introduced CombiPGS, a new preimplantantion genetic screening test for women undergoing in vitro fertilization.
Run using bacterial artificial chromosome arrays from within its Irvine, Calif.-based services laboratory, CombiPGS allows CombiMatrix to enter a "lucrative, cash-pay market," CEO Mark McDonough said in a statement.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
